[ad_1]
BioTelemetry (BEAT) released a quarterly profit of 0.56 USD per share, exceeding Zaken's consensus estimate of 0.42 USD per share. This compares with a profit of $ 0.32 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents a profit surprise of 33.33%. A quarter of a month ago, it was predicted that this manufacturer of cardiac monitoring devices would post a profit of 0.32 USD per share while it was making a profit of 0.53 USD, generating a surprise of 65.63 %.
In the last four quarters, the company has exceeded EPS consensus estimates by four.
BioTelemetry, which belongs to the Zacks medical services sector, recorded a business turnover of $ 103.60 million for the quarter ended December 2018, exceeding by 0.57% the consensus estimate of Zacks. This compares with revenues of $ 91.74 million a year ago. The company has exceeded four times the revenue estimated by consensus over the past four quarters.
The sustainability of the immediate stock price movement based on recently published figures and future earnings forecasts will depend primarily on management's feedback on the call for results.
BioTelemetry's shares have grown about 26.2% since the beginning of the year, compared to 11.1% for the S & P 500.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "What is the next step for biotelemetry?"data-reactid =" 28 ">What is the next step for biotelemetry?
While BioTelemetry has outperformed the market since the beginning of the year, the question for investors is: what is the next step for the stock?
There is no simple answer to this key question, but the company's earnings outlook is a reliable measure to help investors. This includes not only the current consensus results for the coming quarters, but also how these forecasts have changed recently.
Empirical research shows a strong correlation between short-term stock movements and trends in revisions to earnings estimates. Investors can track these revisions themselves, or rely on a proven scoring tool such as Zacks Rank, which has impressive experience operating the revision of earnings power estimates.
Prior to the release of these results, the trend of estimated revisions for BioTelemetry was mixed. Although the magnitude and direction of the revisions may change as a result of the release of the company's earnings report, the current status results in a Zack ranking of 3 percent. the title. As a result, equities should evolve in line with the market in the near future. You can see the complete list of # 1 Zacks stock at current rank (strong buy) here.
It will be interesting to see how the estimates for the coming quarters and the current fiscal year will change in the coming days. The consensus estimate of EPS is currently $ 0.43 on revenue of $ 104.62 million for the next quarter and $ 1.78 on revenue of $ 439.18 million for the fiscal year In progress.
Investors should be aware that the outlook for the sector can also have a significant impact on the performance of the security. With regard to the Zacks industry ranking, medical services are currently in the last 44% of 250 companies and more than Zacks. Our research shows that the top 50% of industries ranked by Zacks perform better than the bottom 50% by a factor greater than 2 to 1.
Do you want to know the latest Zacks Investment Research recommendations? Today, you can download 7 best actions for the next 30 days. Click to get this free report
BioTelemetry, Inc. (BEAT): Free Stock Analysis Report
To read this article on Zacks.com, click here.
[ad_2]
Source link